Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: Impact on local control and patient survival: Clinical article

Journal of Neurosurgery

Volumn 110, Issue 1, 2009, Pages 173-180

  Narayana, Ashwatha ^a   Kelly, Patrick ^a   Golfinos, John ^a   Parker, Erik ^a   Johnson, Glyn ^a   Knopp, Edmond ^a   Zagzag, David ^a   Fischer, Ingeborg ^a   Raza, Shahzad ^a   Medabalmi, Praveen ^a   Eagan, Patricia ^a,b   Gruber, Michael L ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b OVERLOOK HOSPITAL   (United States)

Author keywords

Antiangiogenic therapy; Bevacizumab; High grade glioma

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; IRINOTECAN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; BRAIN TUMOR; DISEASE COURSE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 60649116273     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2008.4.17492     Document Type: Article

References (28)

1. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al: Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843-7848, 2006 (Pubitemid 44299144)
2. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D: Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 223:11-29, 2002 (Pubitemid 34258186)
3. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25:4714-4721, 2007 (Pubitemid 350086472)
4. Gruber ML, Buster WP: Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol 27:33-38, 2004
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
6. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin On col 22:2184-2191, 2004 (Pubitemid 41095154)
7. Kassner A, Roberts TP: Beyond perfusion: cerebral vascular reactivity and assessment of microvascular permeability. Top Magn Reson Imaging 15:58-65, 2004 (Pubitemid 38437545)
8. Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M: Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 9:1399-1405, 2003 (Pubitemid 36418393)
9. Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, et al: Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 25:746-755, 2004 (Pubitemid 38657655)
10. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67, 2006
11. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
12. Mason WP, Cairncross JG: Drug Insight: temozolomide as a treatment for malignant glioma-impact of a recent trial. Nat Clin Pract Neurol 1:88-95, 2005
13. Medical Research Council Brain Tumor Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma. A Medical Research Council trial. J Clin Oncol 19:509-518, 2001
14. Narayana A, Chheang S, Knopp E, Peccerelli N, Babb J, Johnson G, et al: Comparing cerebral blood volume and vascular permeability measurements with tumor volume measurements following anti-angiogenesis therapy in recurrent gliomas. J Clin Oncol 25 (18 Suppl):2030, 2007 (Abstract)
15. Narayana A, Leibel SA: Primary and metastatic brain tumors in adults, in Leibel S, Philips TL (eds): Textbook of Radiation Oncology, ed 2. Philadelphia: Saunders, 2004, pp 471-495
16. Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH, et al: Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys 64:892-897, 2006 (Pubitemid 43183590)
17. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258-1260, 2006 (Pubitemid 43739717)
18. Raizer JJ, Callot L, Cohn R, Chandler J, Levy R, Getch C, et al: A phase II safety study of bevacizumab in patients with mul tiple recurrent or progressive malignant gliomas. J Clin On col 25 (18 Suppl):2079, 2007 (Abstract)
19. Sakariassen PØ, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, Molthoff C, et al: Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A 103:16466-16471, 2006
20. Santarelli JG, Udani V, Yung YC, Cheshier S, Wagers A, Brek ken RA, et al: Incorporation of bone marrow-derived Flk-1-expressing CD34+ cells in the endothelium of tumor vessels in the mouse brain. Neurosurgery 59:374-382, 2006 (Pubitemid 44325883)
21. Stefanik DF, Fellows WK, Rizkalla LR, Rizkalla WM, Stefanik PP, Deleo AB, et al: Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 55:91-100, 2001
22. Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoom MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
23. Traina TA, Rugo HS, Dickler M: Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 21:303-319, 2007
24. Vignjevic D, Schoumacher M, Gavert N, Janssen KP, Jih G, Laé M, et al: Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res 67:6844-6853, 2007
25. Vredenburgh JJ, Desjardins A, Herndon JE II, Dowell JM, Reardon DA, Quinn JA, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259, 2007 (Pubitemid 46424067)
26. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, et al: bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729, 2007 (Pubitemid 350086473)
27. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G: Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9:261-272, 2006
28. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999